CapsoVision Amends Canon Agreement for Upgraded Image Sensors

The latest update is out from CapsoVision, Inc. ( (CV) ).

On March 9, 2026, CapsoVision, Inc. amended its development agreement with Canon Inc. to increase the total fee for developing CMOS image sensor samples by $1 million, reflecting enhanced specification features and raising the remaining development payments accordingly. The parties confirmed that, despite the higher overall cost, the mechanism for paying the remaining development fee and the additional per-unit amount under the forthcoming master purchase arrangement remain unchanged, preserving the structure of CapsoVision’s long-term supply and cost framework for capsule endoscopy image sensors.

This amendment builds on the original agreement under which CapsoVision committed approximately $4.1 million for Canon’s development work, including an initial $1 million cash payment and a remaining fee tied to sensor delivery and performance milestones. By maintaining all other terms in force while accepting higher development costs, CapsoVision secures access to upgraded imaging components that are critical for clinical evaluation and regulatory clearance of its capsule endoscopy devices, potentially strengthening its product capabilities and competitive positioning in the medical imaging market.

The most recent analyst rating on (CV) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on CapsoVision, Inc. stock, see the CV Stock Forecast page.

Spark’s Take on CV Stock

According to Spark, TipRanks’ AI Analyst, CV is a Neutral.

The score is weighed down primarily by weak financial performance (losses, negative equity, and negative operating/free cash flow) and a bearish technical setup (below key moving averages with negative MACD). Positive FDA-related product/regulatory initiatives provide some upside, while valuation data is insufficient to materially improve the rating.

To see Spark’s full report on CV stock, click here.

More about CapsoVision, Inc.

CapsoVision, Inc. operates in the medical device industry, focusing on capsule endoscopy technologies that rely on advanced imaging components. The company’s products depend on high-performance CMOS image sensors, and it collaborates with suppliers such as Canon Inc. to develop and integrate these sensors for clinical use and regulatory clearance in markets like the U.S.

Average Trading Volume: 307,955

Technical Sentiment Signal: Hold

Current Market Cap: $251.1M

See more insights into CV stock on TipRanks’ Stock Analysis page.